Metagenomi Therapeutics, Inc. (MGX) is a clinical-stage, in vivo genome-editing biotech — a company working to edit genes directly inside a patient's body to cure genetic diseases. Its lead program, MGX-001, targets a one-time treatment for hemophilia A. After a steep multi-year decline, the stock trades below $1, while the current analyst-derived price target sits at roughly $7. The question is whether that gap represents genuine upside or a target the market no longer believes.
Metagenomi has unusually thin analyst coverage for a biotech. The two most recently updated targets are Wells Fargo's $7 (Overweight, August 11, 2026) and Chardan Capital's $5 (Buy, July 7, 2026). Recent aggregator data also reflects at least one additional buy-rated target near $9, producing a working range of roughly $5 to $9. The arithmetic mean of those three values is $7.00, which matches the $7.00 one-year consensus estimate reported by Yahoo Finance and by S&P Global-sourced data.
The most important feature of this target set is direction, not disagreement. Every covering analyst remains bullish in rating, yet targets have been cut repeatedly: Wells Fargo has trimmed its target from $20 to $16 to $12 to $9 to $7 over the past year, while Chardan has moved from $12 to $11 to $7 to $5. That pattern reflects shrinking valuation expectations, not a loss of conviction in the underlying science. The $7 figure is best read as a high-risk, high-upside estimate tied to successful clinical execution rather than a near-term trading level.
As of early November 2026, MGX traded near $0.71, just above its 52-week range low of $0.60 and far below its 52-week high of about $2.28. From roughly $0.71, the move to $7 implies approximately 885% upside — a very large gap that separates a beaten-down micro-cap from its analyst objective. Because the company is pre-revenue and deeply unprofitable, conventional valuation metrics such as the P/E (price-to-earnings) ratio are not meaningful here.
A realistic path toward the target would have to be driven by binary clinical and business catalysts: a successful IND filing for MGX-001, commencement of first-in-human dosing, and continued execution on cash-funded operations. In effect, the gap reflects the market pricing near-total uncertainty about whether the platform will advance, while the targets price a materially de-risked clinical program.
MGX trades near the bottom of a steep, long-running downtrend. The 52-week low near $0.60 is the clearest support level, and the stock's position only a few cents above it means downside follow-through is a live risk. On the upside, the round-number $1.00 level is a psychological barrier, followed by the $2.28 zone at the top of the 52-week range. Because the $7 target lies far above any recent trading range, conventional resistance levels are of limited relevance — reaching it would require a fundamental repricing rather than a routine technical breakout.
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms rarely publish a precise date. Investors should watch the Q4 2026 IND submission for MGX-001, any first-patient dosing announcements, quarterly cash and runway updates, collaboration milestones with Ionis and Moderna, and further analyst target revisions. Given how much of the gap to $7 depends on clinical execution, single data points can move the stock dramatically in either direction.
For traders tracking volatile, catalyst-driven names like MGX, Tickeron's AI Daily Buy/Sell Signals offer a data-driven complement to fundamental research. The system uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from shifting market conditions, technical behavior, and AI-driven analysis. That can help traders discover opportunities, monitor existing positions, and spot changing trends more efficiently than manual screening. Consider exploring the AI Daily Buy/Sell Signals to see how automated analysis reads the current tape.
The $7 central target is the arithmetic mean of a small set of analyst targets spanning roughly $5 to $9, and it sits roughly 885% above the current price near $0.71. Support for the figure rests on the MGX-001 clinical program, a planned 2026 IND filing, partnerships, and a cash runway into 2027. The principal obstacles are equally real: clinical-execution risk, repeated downward target revisions, missed quarterly results, restructuring, potential dilution, and litigation. The wide gap between price and target is best understood as the market pricing deep uncertainty against an analyst community that remains structurally bullish. Whether MGX closes that gap depends on clinical catalysts rather than valuation math, and no outcome is assured.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, MGX has been loosely correlated with EDIT. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if MGX jumps, then EDIT could also see price increases.
| Ticker / NAME | Correlation To MGX | 1D Price Change % | ||
|---|---|---|---|---|
| MGX | 100% | -3.01% | ||
| EDIT - MGX | 47% Loosely correlated | -8.91% | ||
| SANA - MGX | 46% Loosely correlated | -1.42% | ||
| VYGR - MGX | 45% Loosely correlated | -8.29% | ||
| BCYC - MGX | 44% Loosely correlated | -2.12% | ||
| RCKT - MGX | 43% Loosely correlated | -3.16% | ||
More | ||||